发明名称 |
High-strength testosterone undecanoate compositions |
摘要 |
The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided. |
申请公布号 |
US9358241(B2) |
申请公布日期 |
2016.06.07 |
申请号 |
US201414298768 |
申请日期 |
2014.06.06 |
申请人 |
LIPOCINE INC. |
发明人 |
Giliyar Chandrashekar;Venkateshwaran Srinivasan;Chickmath Basawaraj;Chidambaram Nachiappan;Patel Mahesh V |
分类号 |
A61K9/48;A61P15/08;A61K31/568;A61K9/16 |
主分类号 |
A61K9/48 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating a hypogonadal male, said method comprising:
administering a daily dose of 430-460 mg or 632 mg of testosterone undecanoate to the hypogonadal male for a period of time, measuring the hypogonadal male's serum testosterone level after said period of time to determine the maintenance regime daily dose, and administering a maintenance regime that provides a daily dose of testosterone undecanoate that is within ±40% of the initial daily dose administered to the hypogonadal male, wherein the testosterone undecanoate is in a pharmaceutical composition comprising (a) a fatty acid, C8 to C22 fatty acid glyceride, or a combination thereof and (b) a polyoxylated hydrogenated vegetable oil, and wherein said method when performed with a group of hypogonadal males provides a) a serum testosterone Cmax of less than 1500 ng/dL in at least 85% of the hypogonadal males in the group; b) a serum testosterone Cmax of about 1800 ng/dL to about 2500 ng/dL in 5% or less of the hypogonadal males in the group; or c) a serum testosterone Cmax greater than 2500 ng/dL in about 1% or less of the hypogonadal males in the group. |
地址 |
Salt Lake City UT US |